<?xml version='1.0' encoding='utf-8'?>
<document id="26303220"><sentence text="A pilot study on the impact of known drug-drug interactions in cancer patients." /><sentence text="When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment" /><sentence text=" Cancer patients are at high risk of such interactions because they commonly receive multiple medications" /><sentence text=" Moreover, most cancer patients are elderly and require additional medications for comorbidities" /><sentence text=" Aim of this preliminary observational study was to evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple treatments" /><sentence text="" /><sentence text="Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with malignant solid tumors who were receiving systemic anticancer treatment" /><sentence text=" Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks" /><sentence text=" DDIs were divided into two different groups: 'neoplastic DDIs' (NDDIs), involving antitumoral drugs, and 'not neoplastic DDIs' (nDDIs), involving all other classes of drugs" /><sentence text=" The severity of DDIs was classified as major, moderate and minor, according to the 'Institute for Pharmacological Research Mario Negri' definition" /><sentence text="" /><sentence text="About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug combinations" /><sentence text=" The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage"><entity charOffset="115-124" id="DDI-PubMed.26303220.s13.e0" text="tamoxifen" /><entity charOffset="129-141" id="DDI-PubMed.26303220.s13.e1" text="capecitabine" /><entity charOffset="146-156" id="DDI-PubMed.26303220.s13.e2" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.26303220.s13.e0" e2="DDI-PubMed.26303220.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26303220.s13.e0" e2="DDI-PubMed.26303220.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26303220.s13.e0" e2="DDI-PubMed.26303220.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26303220.s13.e1" e2="DDI-PubMed.26303220.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26303220.s13.e1" e2="DDI-PubMed.26303220.s13.e2" /></sentence><sentence text=" About 60 % of nDDIs involved acetylsalicylic acid"><entity charOffset="30-50" id="DDI-PubMed.26303220.s14.e0" text="acetylsalicylic acid" /></sentence><sentence text="" /><sentence text="Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided" /><sentence text=" The lack of effective communication among specialists and patients might have a role in determining therapeutic errors" /><sentence text=" Our pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs" /><sentence text="" /></document>